
Bridget K Marcellino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1720442/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Advances, 2018, 2, 3581-3589.	5.2	49
2	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 415-421.	0.4	38
3	Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere, 2021, 5, e549.	2.7	29
4	A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-Âpolycythemia vera/essential thrombocythemia myelofibrosis (post-ÂPV/ET MF). Leukemia Research, 2020, 88, 106272.	0.8	25
5	Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744.	5.2	21
6	Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study. JNCI Cancer Spectrum, 2021, 5, pkaa085.	2.9	15
7	Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Reviews, 2019, 36, 23-31.	5.7	14
8	Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clinical Advances in Hematology and Oncology, 2018, 16, 619-626.	0.3	13
9	Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19. Annals of Hematology, 2021, 100, 833-835.	1.8	11
10	Activation of cytotoxic T cell population and inversion of CD4:CD8 ratio as manifestations of cellular immune response in SARS-COV-2 infection. Journal of Hematopathology, 2020, 13, 197-199.	0.4	8
11	Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 501-507.	1.2	7
12	Management of advanced phase myeloproliferative neoplasms. Clinical Advances in Hematology and Oncology, 2019, 17, 405-411.	0.3	7
13	Pharmacotherapy of Myelofibrosis. Drugs, 2017, 77, 1549-1563.	10.9	5
14	A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. Acta Haematologica, 2019, 142, 105-112.	1.4	5
15	Neuroprotection by dietary restriction and the PPAR transcription complex. Translational Neuroscience, 2012, 3, .	1.4	4
16	A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. Case Reports in Hematology, 2019, 2019, 1-4.	0.4	4
17	Prevalence of Cytopenia in the General Population—A National Health and Nutrition Examination Survey Analysis. Frontiers in Oncology, 2020, 10, 579075.	2.8	3
18	Development of an MDM2 Degrader for Treatment of Acute Leukemias. Blood, 2021, 138, 1866-1866.	1.4	3

#	Article	IF	CITATIONS
19	Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, e63-e64.	1.2	2
20	Recent advances in prognostication and treatment of polycythemia vera. Faculty Reviews, 2021, 10, 29.	3.9	2
21	Dietary Restriction and Glycolytic Inhibition Reduce Proteotoxicity and Extend Lifespan via NHR-49. Current Neurobiology, 2018, 9, 1-7.	1.0	2
22	Acquired amegakaryocytic thrombocytopenia as a rare cause of thrombocytopenia during pregnancy. BMJ Case Reports, 2019, 12, e230361.	0.5	1
23	Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia. Blood, 2018, 132, 5158-5158.	1.4	1
24	Alternatives to intensive treatment in patients with AML. Clinical Advances in Hematology and Oncology, 2021, 19, 526-535.	0.3	1
25	SLAM dunk for myelofibrosis?. Blood, 2019, 134, 789-791.	1.4	0
26	Plasma hemoglobin in COVID-19: authors' reply. Annals of Hematology, 2021, 100, 2127-2127.	1.8	0